Loading...
XSHE
300181
Market cap1.35bUSD
Jul 09, Last price  
13.32CNY
1D
-2.84%
1Q
-15.16%
Jan 2017
45.89%
IPO
228.46%
Name

Zhejiang Jolly Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHE:300181 chart
P/E
14.47
P/S
3.01
EPS
0.92
Div Yield, %
4.50%
Shrs. gr., 5y
2.67%
Rev. gr., 5y
22.76%
Revenues
3.04b
+17.96%
126,585,142164,902,489215,349,830262,655,252279,327,509343,758,925419,415,229514,926,218670,857,129840,037,942679,039,580730,262,646911,163,9751,090,878,1681,457,396,0651,805,155,3641,942,440,4452,577,878,1663,040,763,497
Net income
632m
+24.45%
13,894,15316,642,66031,584,33841,476,73050,927,86662,002,51380,997,531103,184,20884,772,99772,020,42845,140,28620,751,77325,592,84588,801,783179,408,095273,006,655382,936,096507,771,940631,933,714
CFO
412m
+38.63%
16,047,61331,157,75743,892,65664,780,15013,654,67230,509,25729,503,76713,695,17097,128,28958,304,4566,506,36478,284,593128,942,614279,691,036251,798,511318,591,105288,461,038297,047,240411,801,734
Dividend
May 26, 20250.6 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Zhejiang Jolly Pharmaceutical Co., Ltd. is a Chinese enterprise dedicated to the research, manufacturing, and global distribution of traditional Chinese medicinal products. The company's diverse portfolio includes the Wuling capsule, prescribed for conditions such as insomnia, amnesia, heart palpitations, general fatigue, weakness in the lower back and legs, and tinnitus. This capsule also addresses energy deficiency and a weak pulse often linked to an imbalance of the heart and kidneys, or neurasthenia. Additionally, they produce the Lingze tablet, which targets frequent or painful urination, weak or continuous urine flow, and lower back and knee soreness, especially when these symptoms are associated with benign prostatic hyperplasia, kidney insufficiency, or blood stasis. Another offering, the Bailing tablet, serves as an adjunctive treatment for coughs, asthma, back pain, and chronic bronchitis stemming from lung and kidney deficiencies. The firm also markets Linglianhua particles, used to manage symptoms including excessive sweating, sleep disturbances, irritability, heart flutters, vivid dreams, dizziness with tinnitus, lower back and leg weakness, dry stools, an unusual tongue appearance, and a feeble pulse, often seen in perimenopausal syndrome or heart and kidney disharmony. Beyond these traditional Chinese medicine formulations, Zhejiang Jolly Pharmaceutical provides a range of injectable pharmaceuticals, such as azithromycin, clindamycin phosphate, doxapram, pefloxacin mesylate, adenosine cyclophosphate, and sodium nitroprusside. The company further supplies raw medicinal ingredients, including cordyceps cephalosporium, fermented cordyceps, and Wuling powders. Expanding its reach into healthcare services, Zhejiang Jolly Pharmaceutical Co., Ltd. invests in and participates with Deqing No.3 People's Hospital. Established in 2000 and based in Huzhou, China, the entity now known as Zhejiang Jolly Pharmaceutical Co., Ltd. adopted this name in 1998, evolving from its earlier designation, Zhejiang Jolly Pharmaceutical Health Products Co., LTD.
IPO date
Feb 22, 2011
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT